Table 2.
Hepatic encephalopathy risk associated with current proton pump inhibitor use.
| Case N = 13,195 |
Control N = 13,195 |
Crude | Adjusted a | |||||
|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | |||||
| 7 day window Proton pump inhibitor | 1779 | 13.5% | 977 | 7.40% | 2.18 | 1.99–2.39 | 3.13 | 2.33–4.20 |
| 14 day window Proton pump inhibitor | 2459 | 18.6% | 1192 | 9.03% | 2.82 | 2.59–3.08 | 4.77 | 3.81–5.98 |
| 28 day window Proton pump inhibitor | 3155 | 23.9% | 1268 | 9.61% | 3.86 | 3.55–4.21 | 5.60 | 4.63–6.78 |
a Adjusted for cirrhosis etiology, hepatic decompensation at enrollment, Charlson Comorbidity Index score, and medical comorbidities in recent 3 months